文献速递临床微生物临床免疫分子诊断

PATHFAST TB LAM Ag 检测在结核分枝杆菌及非结核分枝杆菌肺病中的临床评价

Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease.
PubMed 文献 · J Clin Microbiol · 2025-11-26

该研究评估 PATHFAST TB LAM Ag 检测在痰标本中诊断肺结核及监测治疗的效果。对 100 份痰标本检测显示 MTBC 灵敏度 75%、培养阴性标本特异度 95%,NTM 培养阳性标本 65% 阳性;纵向标本中 LAM 浓度与治疗时长及培养阳性时间呈负相关。

要点

  • PF-LAM 检测痰标本 MTBC 灵敏度 75%,培养阴性标本特异度 95%。
  • NTM 培养阳性标本 65% 阳性,其中 NTM-PD 患者灵敏度 73%。
  • LAM 浓度与培养阳性时间强相关(ρ=0.915,P<0.0001)。

核心结论

  • PF-LAM 是快速简便的肺结核诊断检测,NTM 交叉反应降低特异度但可能对 NTM-PD 有诊断价值。
  • LAM 浓度与治疗时长及培养阳性时间负相关,提示可用于 TB 治疗监测。

研究设计与样本

  • 诊断性能评估纳入 100 份痰标本:40 份 MTBC 培养阳性、40 份 NTM 培养阳性、20 份两者培养阴性。
  • 治疗监测纳入 19 例肺结核患者的 61 份纵向痰标本,另检测 1 例 NTM-PD 患者的 4 份标本。
  • PF-LAM 为免疫检测,1 小时内自动化化学发光读数定量 LAM。

主要发现

  • MTBC 检测灵敏度 75%,LAM 浓度与培养阳性时间强相关(Spearman ρ=0.915,P<0.0001)。
  • 培养阴性标本特异度 95%。
  • NTM 培养阳性标本 26/40(65%)阳性,其中 19 份来自 NTM-PD 患者,灵敏度 73%。
  • LAM 浓度与治疗时长负相关(ρ=-0.434,P=0.0012),与培养阳性时间负相关(ρ=-0.665,P<0.0001)。

关键数值与推荐

  • MTBC 灵敏度 75%,培养阴性标本特异度 95%。
  • NTM 培养阳性标本阳性率 65%(26/40),NTM-PD 灵敏度 73%。
  • LAM 浓度与培养阳性时间 Spearman ρ=0.915(P<0.0001)。
  • LAM 浓度与治疗时长 ρ=-0.434(P=0.0012),与培养阳性时间 ρ=-0.665(P<0.0001)。

临床怎么用

  • PF-LAM 可用于痰标本肺结核的快速诊断,需注意 NTM 交叉反应导致的特异度下降。
  • 对 NTM-PD 的检测可能提供诊断参考,但需结合其他方法确认。
  • LAM 浓度定量可用于 TB 治疗过程中的细菌负荷监测。

局限性

  • NTM 交叉反应降低特异度,可能影响 TB 诊断特异性。
  • 治疗监测样本量有限(19 例患者 61 份标本),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Diagnosing pulmonary tuberculosis (TB) and monitoring treatment remain challenging. New tools such as the PATHFAST TB LAM assay (PHC Corporation, formerly LSI Medience Corporation, Tokyo, Japan; distributed by BioSynex, France; PF-LAM) may complement microscopy, culture, and NAAT. PF-LAM is an immunoassay quantifying lipoarabinomannan (LAM), a mycobacterial cell wall component, in sputum within 1 hour using an automated chemiluminescent reader. Diagnostic performance was first assessed on 100 sputum samples: 40 culture-positive for Mycobacterium tuberculosis complex (MTBC), 40 culture-positive for nontuberculous mycobacteria (NTM), and 20 culture-negative for both. We then tested 61 longitudinal sputum samples from 19 pulmonary TB patients under treatment. Four additional samples from one patient with NTM pulmonary disease (NTM-PD) were also tested. PF-LAM showed 75% sensitivity for MTBC detection, with a strong correlation between LAM concentration and culture time-to-positivity (Spearman ρ = 0.915, P < 0.0001). Specificity was 95% on culture-negative specimens. The test was also positive for 26/40 (65%) NTM-culture-positive samples. Notably, 19 of these 26 samples were obtained from NTM-PD patients, yielding 73% sensitivity for NTM-PD detection. The assay's potential for treatment monitoring was demonstrated by significant negative correlations between LAM concentration and (a) treatment duration (ρ=-0.434, P = 0.0012) and (b) time to positive culture (ρ=-0.665, P < 0.0001). PF-LAM is a rapid and easy-to-use test for diagnosing pulmonary TB. While NTM cross-reactivity reduces specificity, it may provide diagnostic value for NTM-PD. Results on monitoring TB treatment are promising as no test is currently available for this indication. IMPORTANCE: Effective monitoring of the treatment response is essential for successful tuberculosis (TB) management as prolonged therapies require accurate evaluation to prevent relapse, treatment failure, or drug resistance. This study highlights the diagnostic and treatment-monitoring potential of the PATHFAST TB LAM Ag assay, which quantifies lipoarabinomannan (LAM) concentrations in sputum samples and correlates with bacterial load. For the first time, we also demonstrate the assay's applicability for detecting and monitoring nontuberculous mycobacterial (NTM) pulmonary diseases, which are increasingly prevalent in industrialized countries. The semi-automated, rapid format (<17 minutes) of the PATHFAST TB LAM Ag assay provides a simple and reliable approach for assessing bacillary load during treatment, representing a promising tool for improving patient management and diagnostic efficiency in both TB and NTM-PD.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Fouchet T, Nait Chabane M, Allam C, et al. Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease. J Clin Microbiol. 2025. PMID: 41294343. doi:10.1128/jcm.01269-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。